Dot gov

Official websites use the Texas HHS logo.
The Texas HHS logo means this is an official website of Texas Health and Human Services.

HTTPS

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

1.1. Adults

Maximum recommended daily doses for sedative/hypnotics in adults, including the elderly population, are summarized in Table 1. Prescribed dosages exceeding these recommendations will be reviewed.

Table 1. Maximum Recommended Daily Dosages for Sedative/Hypnotics in Adults: Benzodiazepines1-7
Drug Name Dosage Form/ Strength Maximum Recommended Dosage: Less than or equal to 65 years Maximum Recommended Dosage: Greater than 65 years
estazolam (generics) 1 mg, 2 mg tablets 2 mg 2 mg*
flurazepam (generics) 15 mg, 30 mg capsules 30 mg 15 mg*
temazepam (Restoril®, generics) 7.5 mg, 15 mg, 22.5 mg, 30 mg capsules 30 mg 30 mg*
triazolam (Halcion®, generics) 0.125 mg, 0.25 mg tablets 0.5 mg 0.25 mg*
quazepam (Doral®, generics) 15 mg tablets 15 mg 15 mg*

Legend:

  • * In elderly patients (patients greater than 65 years of age), sedative/hypnotic dosages should be reduced, if possible, as these patients are more sensitive to sedative/hypnotic pharmacologic/adverse effects24.
CaptionXXX
Drug Name Dosage Form/ Strength Maximum Recommended Dosage: Less than or equal to 65 years Maximum Recommended Dosage: Greater than 65 years
phenobarbital+ (generics) 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg, 100 mg tablets; 20 mg/5 mL elixir 400 mg 400 mg*

Legend:

  • + No longer considered acceptable drug class to manage insomnia as safer agents (i.e., benzodiazepines, nonbarbiturates) are available25.
  • * In elderly patients (patients greater than 65 years of age), sedative/hypnotic dosages should be reduced if possible, as these patients are more sensitive to sedative/hypnotic pharmacologic/adverse effects24.
Table 3. Maximum Recommended Daily Dosages for Sedative/Hypnotics in Adults: Non-Benzodiazepine, Benzodiazepine Receptor Agonists1,2,10-17
Drug Name Dosage Form/ Strength Maximum Recommended Dosage: Less than or equal to 65 years Maximum Recommended Dosage: Greater than 65 years
eszopiclone (Lunesta®, generics) 1 mg, 2 mg, 3 mg tablets 3 mg 2 mg
zaleplon (generics) 5 mg, 10 mg capsules 20 mg 10 mg
zolpidem immediate-release (IR) (Ambien®, generics) 5 mg, 10 mg IR tablets 10 mg 5 mg
zolpidem extended-release (ER) (Ambien CR®, generics) 6.25 mg, 12.5 mg ER tablets 12.5 mg 6.25 mg
zolpidem sublingual tablets (Edluar®) 5 mg, 10 mg sublingual tablets 10 mg 5 mg
zolpidem sublingual tablets (generics) 1.75 mg, 3.5 mg sublingual tablets 1.75 mg  (women)
3.5 mg  (men)
1.75 mg
zolpidem lingual spray (Zolpimist®) 5 mg/ actuation 10 mg 5 mg
Table 4. Maximum Recommended Daily Dosages for Sedative/Hypnotics in Adults: Melatonin Receptor Agonists1,2,18,19
Drug Name Dosage Form/Strength Maximum Recommended Dosage: Less than or equal to 65 years Maximum Recommended Dosage: Greater than 65 years
ramelteon (Rozerem®) 8 mg tablets 8 mg 8 mg
ramelteon (Rozerem®, generics) 8 mg tablets 8 mg 8 mg
Table 5. Maximum Recommended Daily Dosages for Sedative/Hypnotics in Adults: Orexin Receptor Antagonists1,2,20-22
Drug Name Dosage Form/Strength Maximum Recommended Dosage: Less than or equal to 65 years Maximum Recommended Dosage: Greater than 65 years
daridorexant (Quviviq®) 25 mg, 50 mg 50 mg 50 mg
lemborexant (Dayvigo®) 5 mg, 10 mg tablets 10 mg 10 mg
suvorexant (Belsomra®) 5 mg, 10 mg 15 mg, 20 mg tablets 20 mg 20 mg
Table 6. Maximum Recommended Daily Dosages for Sedative/Hypnotics in Adults: Miscellaneous Nonbarbiturates1,2,23
Drug Name Dosage Form/Strength Maximum Recommended Dosage: Less than or equal to 65 years Maximum Recommended Dosage: Greater than 65 years
doxepin (Silenor®, generics) 3 mg, 6 mg tablets 6 mg 6 mg

In the elderly, short- and intermediate-acting benzodiazepines (e.g., temazepam, triazolam) are preferred, as long-acting benzodiazepines (e.g., flurazepam) are associated with increased sedation and an increased risk of falls and fractures in this patient population.

The appropriate sedative/hypnotic dose for debilitated patients is the same as that prescribed in elderly patients for most sedative/hypnotic agents. However, estazolam 0.5 mg is used in small or debilitated geriatric patients, a dose lower than that recommended for elderly patients.

Doxepin is FDA-approved for use in managing insomnia characterized by difficulty in maintaining sleep. Studies have documented efficacy for up to 3 months in duration.

Patients with hepatic insufficiency have a reduced clearance of zolpidem. A 5 mg zolpidem immediate-release, sublingual (Edluar®), or oral spray (Zolpimist®) dose, a 1.75 mg sublingual tablet (Intermezzo®) dose, or a 6.25 mg extended-release dose is recommended in these patients.

Eszopiclone should be used cautiously in patients with severe hepatic impairment with initial doses of 1 mg daily at bedtime, as eszopiclone is significantly hepatically metabolized and serum concentrations may increase substantially in this patient population.

Suvorexant and lemborexant are newer sedative/hypnotics with a novel mechanism of action. Known as orexin receptor antagonists, suvorexant and lemborexant works by altering signaling of the orexin neurotransmitters in the brain. Orexins are responsible for regulating the sleep-wake cycle and helping to keep people awake. Suvorexant was FDA-approved in August 2014 as a schedule IV-controlled substance to manage insomnia associated with difficulties in sleep onset and/or sleep maintenance. Lemborexant was FDA-approved in December 2019 as a schedule IV-controlled substance for the treatment of insomnia characterized by difficulties with sleep onset and/ or sleep maintenance.